Posted by Michael Wonder on 08 Mar 2023
Amphastar Pharmaceuticals receives FDA approval for naloxone hydrochloride nasal spray 4 mg
8 March 2023 - Amphastar Pharmaceuticals announced that the US FDA has granted approval of its new drug application for naloxone hydrochloride nasal spray 4 mg, which is delivered utilising the Company's proprietary nasal delivery device.
Naloxone hydrochloride nasal spray 4 mg is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression for adult and paediatric patients.
